HK1018272A1 - Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders - Google Patents

Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders

Info

Publication number
HK1018272A1
HK1018272A1 HK99103334A HK99103334A HK1018272A1 HK 1018272 A1 HK1018272 A1 HK 1018272A1 HK 99103334 A HK99103334 A HK 99103334A HK 99103334 A HK99103334 A HK 99103334A HK 1018272 A1 HK1018272 A1 HK 1018272A1
Authority
HK
Hong Kong
Prior art keywords
pyridylmethylpiperazine
piperidinederivatives
cns
disorders
substituted
Prior art date
Application number
HK99103334A
Other languages
English (en)
Inventor
Martinus T M Tulp
Stephen K Long
Hartog Jacobus A J Den
Roelof W Feenstra
Cornelis G Kruse
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of HK1018272A1 publication Critical patent/HK1018272A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
HK99103334A 1997-09-24 1999-08-03 Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders HK1018272A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97202950 1997-09-24

Publications (1)

Publication Number Publication Date
HK1018272A1 true HK1018272A1 (en) 1999-12-17

Family

ID=8228755

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99103334A HK1018272A1 (en) 1997-09-24 1999-08-03 Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders

Country Status (31)

Country Link
US (2) US6090812A (pt)
EP (1) EP0908458B1 (pt)
JP (1) JP4191826B2 (pt)
KR (1) KR100632188B1 (pt)
CN (1) CN1093857C (pt)
AR (1) AR017127A1 (pt)
AT (1) ATE316529T1 (pt)
AU (1) AU733526B2 (pt)
BR (1) BR9803497A (pt)
CA (1) CA2247734C (pt)
CY (1) CY1107494T1 (pt)
CZ (1) CZ296741B6 (pt)
DE (1) DE69833297T2 (pt)
DK (1) DK0908458T3 (pt)
DZ (1) DZ2613A1 (pt)
ES (1) ES2255127T3 (pt)
HK (1) HK1018272A1 (pt)
HU (1) HU227422B1 (pt)
ID (1) ID20895A (pt)
IL (1) IL126295A (pt)
NO (1) NO312835B1 (pt)
NZ (1) NZ331984A (pt)
PL (1) PL190622B1 (pt)
PT (1) PT908458E (pt)
RU (1) RU2197488C2 (pt)
SI (1) SI0908458T1 (pt)
SK (1) SK285205B6 (pt)
TR (1) TR199801866A1 (pt)
TW (1) TW530054B (pt)
UA (1) UA66756C2 (pt)
ZA (1) ZA988749B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60000405T2 (de) * 1999-01-07 2003-08-07 Wyeth, Madison 1,4-disubstitutierte cyclohexanderivate zur behandlung von depression
US6200994B1 (en) 1999-01-07 2001-03-13 American Home Products Corp 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
DE10115922A1 (de) * 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
ATE424825T1 (de) 2001-07-20 2009-03-15 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US20070275977A1 (en) * 2006-05-02 2007-11-29 Van Aar Marcel P N-oxides of pyridylmethyl -piperazine and -piperidine derivatives
WO2007128694A1 (en) 2006-05-02 2007-11-15 Solvay Pharmaceuticals B.V. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
WO2011088838A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands
US8877778B2 (en) * 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
TWI712598B (zh) 2016-07-20 2020-12-11 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
KR101665971B1 (ko) 2016-08-10 2016-10-13 (주)글로벌 로보틱스 차량용 발포패드 부착장치
US11738026B2 (en) 2019-11-22 2023-08-29 Incyte Corporation Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
KR20230025444A (ko) 2020-06-16 2023-02-21 인사이트 코포레이션 빈혈 치료를 위한 alk2 저해제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3571436D1 (en) * 1984-12-21 1989-08-17 Duphar Int Res New pharmaceutical compositions having anti-psychotic properties
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
NZ219380A (en) * 1986-02-27 1990-06-26 Duphar Int Res (n-piperidinyl)- and (n-piperazinyl)-methylazole derivatives and pharmaceutical compositions
EP0508347A1 (en) 1991-04-10 1992-10-14 Hoechst Aktiengesellschaft 5,7-Dihydroxy-2-methyl-8-[4-(3-hydroxy-1-(1-propyl)) piperidinyl]-4H-1-benzopyran-4-one, its preparation and its use
IE914218A1 (en) * 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
JPH05262765A (ja) 1992-03-18 1993-10-12 Sumitomo Chem Co Ltd ベンゾフラン誘導体およびそれを有効成分とする除草剤
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
GB9314758D0 (en) * 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
AU6517196A (en) * 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO1997036893A1 (en) * 1996-03-29 1997-10-09 Duphar International Research B.V. Piperazine and piperidine compounds
DE19637237A1 (de) * 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate

Also Published As

Publication number Publication date
USRE41425E1 (en) 2010-07-06
PT908458E (pt) 2006-05-31
DK0908458T3 (da) 2006-06-06
DE69833297T2 (de) 2006-07-20
JPH11302279A (ja) 1999-11-02
EP0908458B1 (en) 2006-01-25
KR100632188B1 (ko) 2007-04-25
HU9802129D0 (en) 1998-11-30
NO312835B1 (no) 2002-07-08
ID20895A (id) 1999-03-25
TW530054B (en) 2003-05-01
US6090812A (en) 2000-07-18
CA2247734A1 (en) 1999-03-24
ES2255127T3 (es) 2006-06-16
DE69833297D1 (de) 2006-04-13
JP4191826B2 (ja) 2008-12-03
AR017127A1 (es) 2001-08-22
EP0908458A1 (en) 1999-04-14
NZ331984A (en) 2000-02-28
SK129498A3 (en) 1999-04-13
AU733526B2 (en) 2001-05-17
HUP9802129A1 (hu) 2000-03-28
BR9803497A (pt) 2000-05-02
PL190622B1 (pl) 2005-12-30
CY1107494T1 (el) 2013-03-13
IL126295A0 (en) 1999-05-09
IL126295A (en) 2003-02-12
ATE316529T1 (de) 2006-02-15
PL328754A1 (en) 1999-03-29
DZ2613A1 (fr) 2003-03-01
TR199801866A1 (xx) 1999-04-21
ZA988749B (en) 1999-03-26
CA2247734C (en) 2007-08-07
UA66756C2 (uk) 2004-06-15
NO984380D0 (no) 1998-09-21
HU227422B1 (en) 2011-05-30
SK285205B6 (sk) 2006-08-03
CN1220265A (zh) 1999-06-23
RU2197488C2 (ru) 2003-01-27
KR19990029982A (ko) 1999-04-26
CZ303098A3 (cs) 1999-04-14
SI0908458T1 (sl) 2006-06-30
CN1093857C (zh) 2002-11-06
AU8607998A (en) 1999-04-15
NO984380L (no) 1999-03-25
CZ296741B6 (cs) 2006-06-14

Similar Documents

Publication Publication Date Title
HK1018272A1 (en) Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders
PL324313A1 (en) 10-axcyloxy 10,11-dihydrobenz/b,f/azepin-5-carboxyamides useful in treating nervous system disorders
PL336290A1 (en) Sulphonamides for treating endothelin-involving disorders
AU8769098A (en) System for treating patients with anxiety disorders
HUP9701096A3 (en) Use of benzenesulfonamides for the preparation of pharmaceutical compositions treating disorders of the central nervous system, novel derivatives, process for their preparation and pharmaceutical compositions containing them
AU2423697A (en) System for treating patients with anxiety disorders
PL341596A1 (en) Pharmacological composition for treating concentration disorders and hyperkinesia
HUP0001237A3 (en) Methods for treating vascular disorders
PL363219A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
ZA982877B (en) Treatment of central nervous system disorders with selective estrogen receptor modulators.
HUP0003964A2 (en) Methods for treating thrombotic disorders
EP0996456A4 (en) PROCESS FOR TREATING NEUROLOGICAL DEFICITS
AU2384500A (en) Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
ZA967944B (en) Substituted cyclohexylamines as central nervous system agents
EP0419247A3 (en) Selective gaba antagonists, especially isoquinoline derivatives, and their use for treating cns disorders
EP1011330A4 (en) REGENERATION OF AXONES IN THE CENTRAL NERVOUS SYSTEM
PL345110A1 (en) Aza-heterocyclic compounds used to treat neurological disorders and hair loss
PL341392A1 (en) Triazinic compounds for treating cns disorders
PL332821A1 (en) Pyrazolydinones for treating potency disorders
EP0679397A3 (de) Verwendung von substituierten Aminen zur Behandlung von Hirnleistungsstörungen.
AU4239597A (en) Novel pharmacotherapeutic process and composition for central nervous system disorders
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
AU2003204221A1 (en) Dipyridoimidazolderivatives useful in treating central nervous system disorders
EP1094863A4 (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL INJURIES AND DISEASES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120921